Epizyme (NASDAQ: EPZM) is one of 306 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Epizyme to related companies based on the strength of its institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.
Volatility & Risk
Epizyme has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, Epizyme’s rivals have a beta of 5.98, suggesting that their average share price is 498% more volatile than the S&P 500.
Institutional & Insider Ownership
71.0% of Epizyme shares are held by institutional investors. Comparatively, 50.6% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 25.2% of Epizyme shares are held by company insiders. Comparatively, 16.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Epizyme and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Epizyme and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Epizyme||$8.01 million||-$110.21 million||-6.28|
|Epizyme Competitors||$288.09 million||$35.08 million||143.88|
Epizyme’s rivals have higher revenue and earnings than Epizyme. Epizyme is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current ratings and target prices for Epizyme and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Epizyme currently has a consensus target price of $23.00, suggesting a potential upside of 61.40%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.43%. Given Epizyme’s stronger consensus rating and higher possible upside, research analysts plainly believe Epizyme is more favorable than its rivals.
Epizyme beats its rivals on 7 of the 12 factors compared.
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company’s lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.